ILMN

Illumina Inc

Fortis Capital Advisors LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The...

Asset Management One Co. Ltd. grew its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 10.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and...

KBC Group NV raised its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 53.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,007 shares of the life sciences company's stock after pur...

Cwm LLC lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 22.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange...

TEM expands GenoPredicta rollout and deepens oncology partnerships, leveraging AI and WGS to advance cancer diagnostics and research.

DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base...

Robeco Institutional Asset Management B.V. trimmed its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 9.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 70,997 shares of the life sciences compan...

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eighteen ratings firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and...

Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease Illumina and the Center for...